



# Share subscriptions based on the resolution by Nanoform Finland Plc's Annual General Meeting 2024 on remuneration of the Board of Directors

Company release

**Nanoform Finland Plc**

June 14, 2024

17:00 Finnish time / 16.00 Swedish time

## Share subscriptions based on the resolution by Nanoform Finland Plc's Annual General Meeting 2024 on remuneration of the Board of Directors

**Helsinki, Finland** – A total of 85,072 Nanoform Finland Plc's (the "**Company**" or "**Nanoform**") new shares has been subscribed for by the members of the Board of Directors of the Company. The shares are issued as part of remuneration of the members of the Board of Directors in accordance with the resolution by the Company's Annual General Meeting April 16, 2024 (the "**AGM**"). As noted in the AGM, the share price 2.01 euros corresponds to volume-weighted average share price over ten (10) trading days following the publication of the interim report of the Company for 1 January 2024 – 31 March 2024 (the "**Q1 Report**"). The Q1 Report was published on May 30, 2024.

The entire subscription price of EUR 171,000 for the share subscriptions will be entered in the Company's reserve for invested unrestricted equity. The shares subscribed for are expected to be registered in the Trade Register on or about June 25, 2024, as of which date the new shares will establish shareholder rights and the total amount of shares in the Company will be 85,530,236. The shares will be traded on the NASDAQ Helsinki Plc's First North Growth Market Finland marketplace together with the old shares on or about June 26, 2024.

For further information, please contact:

Peter Hänninen, General Counsel

[peter.hanninen@nanoform.com](mailto:peter.hanninen@nanoform.com)

+358 50 353 0408

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

[hvh@nanoform.com](mailto:hvh@nanoform.com)

+46 7686 650 11

[About Nanoform](#)

Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP nano-API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanofarming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and

extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit [www.nanoform.com](http://www.nanoform.com).